Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastasesNina Zila(Medical University of Vienna), Verena Paulitschke(University Hospital of Zurich)Clinical ProteomicsMarch 9, 201810.1186/s12014-018-9189-xCited by 19SaveCiteExport RISWatch citationsRelated PapersROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma|Cancer Research|2023|24Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma|Unknown|2023|0